Uterine sarcoma: Twenty-seven years of experience

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 5, 2003, Pages 1366-1373

  Livi, L ^a   Paiar, F ^a   Shah, N ^b   Blake, P ^c   Villanucci, A ^a   Amunni, G ^a   Barca, R ^a   Judson, I ^c   Lodge, N ^c   Meldolesi, E ^a   Simontacchi, G ^a   Piperno, G ^a   Galardi, A ^a   Scoccianti, S ^a   Biti, G P ^a   Harmer, C ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Brachytherapy; Radiotherapy; Uterine sarcoma

Indexed keywords

DOSIMETRY; HISTOLOGY; PATHOLOGY; PATIENT MONITORING; RADIOTHERAPY; SURGERY; TUMORS;

EXTERNAL BEAM RADIOTHERAPY;

BIOMEDICAL ENGINEERING;

ADULT; AGE DISTRIBUTION; AGED; ANALYTIC METHOD; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DEATH; ENDOMETRIUM SARCOMA; FEMALE; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MIXED MULLERIAN TUMOR; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RHABDOMYOSARCOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM; UTERUS SARCOMA;

EID: 0345257812     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00750-8     Document Type: Article

References (34)

1. Olah K.S., Gree H., Blunt S., , et al. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer. 27:1991;1095-1099.
2. Marchese M.J., Liskow A.S., Crum C.P., McCaffrey R.M., Frick H.C. 2nd. Uterine sarcomas A clinicopathologic study, 1965-1981 . Gynecol Oncol. 18:1984;299-312.
3. Hermanek P, Hutter R, Sobin L, Wagner G, Wittekind C. TNM atlas. Springer; 1997.
4. Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol. 38:1988;233-239.
5. Gadducci A., , et al. Surgery and radiotherapy in the treatment of early stage uterine sarcomas. Eur J Gynaecol Oncol. 10:1989;276-280.
6. Moskovic E., MacSweeney E., Law M., Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma A study of 76 patients . Br J Radiol. 66:1993;1009-1015.
7. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 27:2001;282-285.
8. Hornback N.B., Omura G., Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 12:1986;2127-2130.
9. Gerszlen K, Faul C, Kounelis S. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:8-13.
10. Bai P., Sun J., Chao H. [A clinical analysis of 153 uterine sarcomas]. Zhonghua Fu Chan Ke Za Zhi. 32:1997;163-167.
11. Coquard R, et al. [Uterine sarcoma treated by surgery and postoperative radiation therapy. Patterns of relapse, prognostic factors and role of radiation therapy]. Bull Cancer 1997;84:625-629.
12. Knocke T., Kucera H., Dorfler D., Pokrajac B., Potter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer. 83:1998;1972-1979.
13. Nordal R.R., Kristensen G.B., Kaern J., , et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34:1995;797-802.
14. Nordal R.R., Kristensen G.B., Stenwig A.E., , et al. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol. 67:1997;316-321.
15. Nordal R.R., Thoresen S.O. Uterine sarcomas in Norway 1956-1992 Incidence, survival and mortality . Eur J Cancer. 33:1997;907-911.
16. Olah K.S., Dunn J.A., Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors The result of a retrospective study of 423 cases of uterine sarcoma . Br J Obstet Gynaecol. 99:1992;590-594.
17. Chauveinc L., Deniaud E., Plancher C., , et al. Uterine sarcomas The Curie Institut experience. Prognosis factors and adjuvant treatments . Gynecol Oncol. 72:1999;232-237.
18. Bodner-Adler B., Bodner K., Obermair A., , et al. Prognostic parameters in endometrial stromal sarcoma A clinicopathologic study in 31 patients . Gynecol Oncol. 81:2001;160-165.
19. Yamada S.D., Burger R.A., Brewster W.R., , et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 88:2000;2782-2786.
20. Watanabe Y., Roy J.N., Harrington P.J., Anderson L.L. Three-dimensional lookup tables for Henschke applicator cervix treatment by HDR 192IR remote afterloading. Int J Radiat Oncol Biol Phys. 41:1998;1201-1207.
21. Verellen D., De Neve W., Van den Heuvel F., , et al. On the determination of the effective transmission factor for stainless steel ovoid shielding segments and estimation of their shielding efficacy for the clinical situation. Med Phys. 21:1994;1677-1684.
22. Ferrer F., Sabater S., Farrus B., , et al. Impact of radiotherapy on local control and survival in uterine sarcomas A retrospective study from the Grup Oncologic Catala-Occita . Int J Radiat Oncol Biol Phys. 44:1999;47-52.
23. Hoffmann W., Schmandt S., Kortmann R.D., , et al. Radiotherapy in the treatment of uterine sarcomas. A retrospective analysis of 54 cases. Gynecol Obstet Invest. 42:1996;49-57.
24. Riddle P.J., Echeta C.B., Manek S., , et al. Retrospective study of management of uterine sarcomas at Oxford 1990-1998 Role of adjuvant treatment . Clin Oncol (R Coll Radiol). 14:2002;54-61.
25. Rose P.G., Eifel P.J. Combined radiation therapy and chemotherapy for carcinoma of the cervix. Cancer J. 7:2001;86-94.
26. Wobbes T., Baron B., Paillot B., , et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer. 37:2001;470-477.
27. Wang X., Masters J.R., Wong Y.C., Lo A.K., Tsao S.W. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Res. 21:2001;403-408.
28. Gadducci A., Romanini A. Adjuvant chemotherapy in early stage uterine sarcomas An open question . Eur J Gynaecol Oncol. 22:2001;352-357.
29. Gershenson D.M., Kavanagh J.J., Copeland L.J., , et al. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol. 5:1987;618-621.
30. Kushner D.M., Webster K.D., Belinson J.L., , et al. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol. 78:2000;221-227.
31. Omura G.A., Blessing J.A., Major F., , et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas A Gynecologic Oncology Group Study . J Clin Oncol. 3:1985;1240-1245.
32. Tore G., Topuz E., Bilce N., , et al. The role of adjuvant chemotherapy in the treatment of uterine sarcoma patients. Eur J Gynaecol Oncol. 11:1990;307-312.
33. Szlosarek P.W., Lofts F.J., Pettengell R., , et al. Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anticancer Drugs. 11:2000;275-278.
34. Wang C.J., Leung S.W., Chen H.C., , et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma Evidence suggestive of consequential late effect (CQLE) . Int J Radiat Oncol Biol Phys. 40:1998;85-91.